Hepatology

Peginterferon alfa-2a, ribavirin

PBAC's latest decision on Peginterferon alfa-2a, ribavirin: Recommended with restriction (2010). Considered for Treatment of chronic hepatitis C in patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated).

PBAC outcome

Recommended with restriction

Authority Required

ICER (AUD/QALY)

Cost-min

cost-minimisation analysis

Submissions

first 2010

Submissions

2010 → 2010

Eligible population

Patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated).

Therapy area: Hepatology
Line of therapy: Later-line
Evidence base: RCT, non-comparative studies
Primary endpoint: SVR
Key trials: Scotto 2008, REPEAT, METRO, HALT-C, WV16143, EPIC-3
Comparator: peginterferon alfa-2b plus ribavirin (Pegatron CT)
Economic model: Cost-minimisation
ICER note: Cost-minimisation analysis performed; no ICER calculated

Open on full dashboard →